Prothena (NASDAQ:PRTA - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06), Zacks reports. The firm had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.
Prothena Stock Up 2.0 %
PRTA traded up $0.31 during trading on Friday, hitting $15.56. The company's stock had a trading volume of 732,645 shares, compared to its average volume of 299,628. Prothena has a twelve month low of $11.70 and a twelve month high of $31.03. The stock's fifty day moving average price is $14.33 and its 200-day moving average price is $16.77. The firm has a market capitalization of $837.28 million, a P/E ratio of -6.77 and a beta of 0.08.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Oppenheimer boosted their price target on Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a report on Friday, February 7th. Royal Bank of Canada cut their price objective on Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday. Bank of America cut their price objective on Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research note on Thursday, December 19th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Prothena in a research note on Friday. Finally, StockNews.com lowered Prothena from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.83.
Check Out Our Latest Stock Report on Prothena
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
See Also
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
